rs11672691: Prostate Cancer Risk and Prognosis Explained
The genetic variant rs11672691 is a single nucleotide polymorphism (SNP) located on chromosome 19. It has been identified in large-scale studies as being associated with an increased risk of developing prostate cancer and a higher likelihood of prostate cancer-specific mortality.
What each genotype means
Baseline risk profile
This genotype represents the baseline state for this variant. Research indicates that individuals with this genotype do not carry the specific risk-associated alleles linked to increased prostate cancer-specific mortality.
The frequency of this genotype varies by ancestry, but it is generally considered the reference state in most populations.
Slightly increased risk
This genotype is associated with a 1.18x increased risk of prostate cancer-specific mortality for individuals who have already been diagnosed with prostate cancer. This association is based on statistical observations in clinical studies and does not imply a diagnosis.
This is a relatively common genotype found across various ancestral groups.
Increased risk profile
For individuals already diagnosed with prostate cancer, this genotype is associated with a 1.39x increased risk of dying from causes related to the cancer. This suggests a potential association with more aggressive disease progression, though it is not a diagnostic tool.
This is a relatively common genotype observed in populations studied for prostate cancer susceptibility.
Understanding rs11672691
A single nucleotide polymorphism, or SNP, is a variation at a single position in a DNA sequence among individuals. The variant rs11672691 is located on chromosome 19 at position 41,479,679 (GRCh38). This specific location is situated within a region associated with the gene PCAT19. In the context of human genetics, rs11672691 is categorized as a trait-associated variant. Researchers study such variants to understand how subtle differences in our genetic code might contribute to complex health conditions. While the presence of a specific allele at this location does not cause prostate cancer directly, it serves as a marker that researchers use to investigate the biological pathways that may influence tumor development and the aggressiveness of the disease in affected individuals.
The Role of PCAT19
The variant rs11672691 is closely linked to the expression of PCAT19, which stands for Prostate Cancer Associated Transcript 19. PCAT19 is a long non-coding RNA (lncRNA). Unlike protein-coding genes that provide instructions for building cellular machinery, lncRNAs often act as regulators of gene expression. Research suggests that the risk-associated G allele of rs11672691 can influence promoter-enhancer switching, which in turn increases the transcript levels of both PCAT19 and a neighboring gene, CEACAM21. These molecules are thought to play roles in cell growth and tumor progression. By modulating the activity of these genes, the variant may create a cellular environment that is more conducive to the development of aggressive prostate cancer, potentially impacting how the disease behaves once it has been diagnosed.
Research and Evidence Strength
The evidence linking rs11672691 to prostate cancer is considered moderate and is supported by multiple genome-wide association studies (GWAS). A meta-analysis involving thousands of prostate cancer patients and control samples identified this variant as being associated with increased susceptibility to the disease. Furthermore, studies have specifically linked the G allele to a higher risk of prostate cancer-specific mortality (PCSM) and more aggressive disease at the time of diagnosis. While these statistical associations are robust across large cohorts, it is important to note that genetic risk is only one piece of a much larger puzzle. Prostate cancer is a multifactorial condition influenced by a combination of genetics, environmental factors, and lifestyle. The presence of this variant does not guarantee a specific health outcome, and the clinical significance of this SNP is still an active area of ongoing scientific investigation.
Interpreting Your Genetic Information
If you have information about your genotype for rs11672691, it is essential to view it within the context of your overall health. This variant is a tool for researchers to understand disease mechanisms, not a diagnostic test for individuals. You cannot use this information to predict your personal risk of developing prostate cancer or to determine your prognosis. Genetic associations are based on population-level data and do not account for the unique medical history or clinical presentation of an individual. If you are concerned about prostate cancer, the most effective approach is to consult with a healthcare professional. They can provide personalized screening recommendations based on your age, family history, and other established clinical risk factors. Never make medical decisions based solely on genetic data found in consumer reports or online databases.
How common is this variant?
The frequency of the rs11672691 alleles varies across different ancestral populations, though specific global frequency percentages are not consistently documented in standard clinical databases.
Frequently asked questions
Does having the G allele mean I will get prostate cancer?
No. Genetic variants like rs11672691 are associated with statistical risk at a population level, not individual certainty. Many people with the G allele never develop prostate cancer, and many without it do.
Should I get tested for rs11672691?
There is currently no clinical recommendation to test for this specific SNP. Prostate cancer screening is typically based on PSA levels and digital rectal exams as advised by your doctor.
How does this variant affect prostate cancer treatment?
Current research focuses on how this variant influences disease progression and mortality, but it is not currently used to guide specific treatment choices. Always discuss your treatment plan with an oncologist.
Where can I find more information on prostate cancer genetics?
You can explore resources like the GWAS Catalog or MedlinePlus Genetics for general information on the genetic architecture of prostate cancer. Always consult a medical professional for advice specific to your health.
Sources & further reading
Educational information only, last refreshed 10/9/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs11672691?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29